Right off the bat, the high-profile departure of Peter Marks, M.D., Ph.D., former director of the FDA’s Center for Biologics ...

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team.

Following a second measles-related death in Texas, Robert F. | The HHS secretary called out the measles vaccines as "the most ...

Although President Donald Trump’s “Liberation Day” tariffs have spared pharmaceuticals, potential drug-specific import taxes ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its ...

Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Over the last several years, drugmakers have agreed to pay $57 billion in opioid settlements, including a landmark $26 ...

On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract ...

While pharma giants Novo Nordisk and Eli Lilly may have a solid hold on the obesity arena, Rhythm Pharmaceuticals is looking ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. | Art Garfunkel is breaking the ...